Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dolorin junior endaþarmsstíll 125 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 125 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dolorin junior endaþarmsstíll 250 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 250 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dolorin junior mixtúra, lausn 24 mg/ml
williams & halls ehf. - paracetamolum inn - mixtúra, lausn - 24 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dolovet vet duft til inntöku 160 mg/ g
vetcare oy - ketoprofenum inn - duft til inntöku - 160 mg/ g
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dolorin tafla 500 mg
williams & halls ehf - paracetamolum inn - tafla - 500 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
qdenga
takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - fjölmörgum - bóluefni - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
pirfenidone axunio (previously pirfenidone aet)
axunio pharma gmbh - pirfenidone - idiopathic lungvefi - Ónæmisbælandi lyf - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
menveo
gsk vaccines s.r.l. - meningókokka hóp a, c, w-135 og y samtengd bóluefni - immunization; meningitis, meningococcal - bakteríubóluefni - vialsmenveo er ætlað fyrir virk bólusetningar sem börn (frá tveggja ára aldri), unglingum og fullorðnir í hættu af völdum neisseria meningitidis tekur, c, w135 og y, til að koma í veg fyrir innrásar sjúkdómur. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - inflúensu, manna - inflúensu bóluefni, inflúensu, lifandi, bæklaða - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. notkun fluenz tetra ætti að byggjast á opinberum ráðleggingum.